Finerenone (Kerendia) significantly reduced albuminuria in adult patients with type 1 diabetes and chronic kidney disease (CKD).[3] The phase III FINE-ONE trial met its primary endpoint with this result.[3] Treatment lasted 6 months and the change in urinary albumin-creatinine ratio (UACR) was evaluated.[3] Finerenone acts as a blocker of mineralocorticoid receptors.[1] In previous studies such as FIDELIO-DKD and FIGARO-DKD (in type 2 diabetes), finerenone reduced the risk of CKD progression and cardiovascular events.[2][6] The FIDELIO-DKD study included 2827 patients treated with doses of 10 or 20 mg daily for approximately 2.2 years.[2] In a pooled analysis of these studies, finerenone caused an initial decrease in eGFR of 2 mL/min/1.73 m² that was reversible.[1]